Wang, Y; Nie, Y; Ding, Z; Yao, MY; Du, R; Zhang, L; Wang, S; Li, DX; Wang, YL; Cao, MW
Development of efficient gene vectors is of great importance for promoting gene therapy. An amphiphilic peptide with the sequence of Ac-RGDGPLGLAGI(3)GR(8)-NH2 (RR-22) has been designed for gene delivery applications. The peptide is a bolaform amphiphile in nature by having two charged segments distributed at the two terminals and a hydrophobic segment in the middle. The R-8 segment is a highly positively charged cell membrane-penetrating sequence that can bind strongly with both DNA and cell membranes. The hydrophobic segment can provide hydrogen bonding and hydrophobic interactions to drive peptide self-assembly. With these characteristics, RR-22 can induce efficient DNA condensation into compact nanoparticles by synergistic effects of electrostatic interaction and peptidic association, a mechanism that is different from those of cationic polyelectrolytes and surfactants. The condensates can resist enzymatic degradation of DNA and ensure successful DNA delivery into cells. More specifically, RR-22 can mediate a quite high level of gene transfection as confirmed by using pEGFP-N2 as a reporter gene to express green fluorescent protein (GFP) in 293E cells. This study illustrates a potential design strategy for developing peptidic gene delivery systems with enhanced DNA condensing ability and gene transfection level.
Keywords: Amphiphilic peptide; Cell penetrating peptide; Gene delivery; DNA condensation; Gene transfection
Cell-Penetrating Peptides (CPPs) are short sequences of amino acids that facilitate the delivery of various molecular cargos, including nucleic acids, into cells, making them a powerful tool for highly efficient gene transfection. CPPs function by directly translocating across the cellular membrane or by endocytosis, enabling them to deliver therapeutic genes, siRNA, or other genetic materials into a wide range of cell types. The versatility of CPPs lies in their ability to penetrate cells without causing significant toxicity or immune responses, which is a crucial advantage over traditional transfection methods. By conjugating with nucleic acids, CPPs form stable complexes that protect genetic material from degradation and enhance cellular uptake. This results in improved transfection efficiency, making CPPs an attractive option for gene therapy, cancer treatment, and other biomedical applications. Their ability to bypass the endosomal barrier further enhances their potential, positioning CPPs at the forefront of non-viral gene delivery technologies.
Product Name | Catalog | Unit Size | Price |
---|---|---|---|
740 Y-P | CDCCP23-001L | 1 mg, 5 mg, 10 mg, 50 mg | INQUIRY |
11R-VIVIT TFA | CDCCP23-029L | 1 mg, 5 mg, 10 mg, 50 mg, 100 mg | INQUIRY |
(Arg)9 Acetate | CDCCP23-046L | 1 mg, 5 mg, 10 mg, 50 mg, 100 mg | INQUIRY |
(Arg)9 TFA | CDCCP23-055L | 1 mg, 5 mg | INQUIRY |
740 Y-P TFA | CDCCP23-057L | 50 mg, 100 mg, 250 mg | INQUIRY |
(Arg)9, FAM-labeled | CDCCP23-059L | 1 mg, 5 mg, 10 mg, 50 mg, 100 mg | INQUIRY |
Biotin-TAT (47-57) | CDCCP23-060L | 1 mg, 5 mg, 10 mg, 50 mg, 100 mg | INQUIRY |
(Arg)9 | CDCCP23-068L | 50 mg, 100 mg, 250 mg | INQUIRY |
Cys-TAT (47-57) | CDCCP23-069L | 50 mg, 100 mg, 250 mg | INQUIRY |
Anti-BetaGamma | CDCCP23-073L | 50 mg, 100 mg, 250 mg | INQUIRY |
(Arg)9 Biotin labeled | CDCCP23-085L | 50 mg, 100 mg, 250 mg | INQUIRY |
Cyclic PSAP Peptide | CDCCP23-098L | 50 mg, 100 mg, 250 mg | INQUIRY |
AGR | CDCCP23-110L | 50 mg, 100 mg, 250 mg | INQUIRY |
11R-VIVIT | CDCCP23-115L | 50 mg, 100 mg, 250 mg | INQUIRY |
Cys(Npys)-TAT (47-57) | CDCCP23-119L | 50 mg, 100 mg, 250 mg | INQUIRY |
(Arg)9, TAMRA-labeled | CDCCP23-128L | 50 mg, 100 mg, 250 mg | INQUIRY |
Antennapedia Peptide FAM-labeled | CDCCP23-137L | 50 mg, 100 mg, 250 mg | INQUIRY |
293P-1 | CDCCP23-139L | 50 mg, 100 mg, 250 mg | INQUIRY |
(Cys47)-HIV-1 Tat Protein (47-57) | CDCCP23-146L | 50 mg, 100 mg, 250 mg | INQUIRY |
Arg-Gly-Asp-Ser TFA | CDCCP23-148L | 50 mg, 100 mg, 250 mg | INQUIRY |